Trovagene Gains 3% On Favorable Mention In Medical Journal

Shares of TrovaGene Inc TROV, a molecular diagnostic company, gained more than 2 percent on Friday after the company announced that it was favorably mentioned in a medical journal.

TrovaGene said a patient case report feature use of its Precision Cancer Monitoring technology was published in 'Cancer Discovery,' a leading oncology journal. The report was authored by Dr. Samuel Klempner, Director of Precision Medicine at The Angeles Clinic and Research Institute in Los Angeles.

"This patient case supports using ctDNA from a urine sample to confirm the presence of the BRAF V600E mutation, and to regularly monitor changes in mutation frequency, especially in the first few weeks of a new drug regimen," stated Dr. Klempner. "Trovagene's liquid biopsy technology provided important evidence of early response to treatment with combination BRAF-MEK inhibitor therapy in BRAF mutant high grade colorectal neuroendocrine tumors. This drug combination is undergoing clinical investigation across multiple tumor types and the information provided by non-invasive dynamic monitoring of ctDNA can be helpful in demonstrating that this novel treatment regimen is having its intended effect."

"We are very pleased with the Cancer Discovery publication, and the ability of our liquid biopsy technology to help physicians select the most appropriate therapy for their patients," stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. "This publication provides a strong example of the potential for personalized medicine, with the disease being classified and treated based on genomic information, and the use of early response biomarkers to rapidly confirm treatment effect. At Trovagene, we believe this is the way cancer will be treated in the future."